NCT04855955

Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease

NO LONGER AVAILABLE Last updated 7 February 2024

What this trial tests

trial testing Adipose-Derived Mesenchymal Stem Cells in Alzheimer Disease. No longer available.

Quick facts

Lead sponsor	Celltex Therapeutics Corporation
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS

Drugs / interventions tested

• Adipose-Derived Mesenchymal Stem Cells — full drug profile →

Conditions studied

• Alzheimer Disease — all drugs for Alzheimer Disease →

Sponsor

Celltex Therapeutics Corporation — full company profile →

Who can join

Eligibility, any sex, with Alzheimer Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject will be evaluated for disease-associated severity according to symptoms, cognitive function, memory, and quality of life.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. A Brief Overview of Global Trends in MSC-Based Cell Therapy.
   Jovic D, Yu Y, Wang D, Wang K, et al · · 2022 · cited 186× · PMID 35344199 · DOI 10.1007/s12015-022-10369-1
2. Mesenchymal Stem Cell Therapy for Alzheimer's Disease.
   Hernández AE, García E. · · 2021 · cited 53× · PMID 34512767 · DOI 10.1155/2021/7834421
3. Exosomes in Precision Oncology and Beyond: From Bench to Bedside in Diagnostics and Therapeutics.
   Youssef E, Palmer D, Fletcher B, Vaughn R. · · 2025 · cited 40× · PMID 40149276 · DOI 10.3390/cancers17060940
4. Mesenchymal stromal cells for the treatment of Alzheimer's disease: Strategies and limitations.
   Regmi S, Liu DD, Shen M, Kevadiya BD, et al · · 2022 · cited 40× · PMID 36277497 · DOI 10.3389/fnmol.2022.1011225
5. Mesenchymal stromal cell-derived secretome-based therapy for neurodegenerative diseases: overview of clinical trials.
   Ghasemi M, Roshandel E, Mohammadian M, Farhadihosseinabadi B, et al · · 2023 · cited 34× · PMID 37143147 · DOI 10.1186/s13287-023-03264-0
6. Advances in stem cell therapy in Alzheimer's disease: a comprehensive clinical trial review.
   Karvelas N, Bennett S, Politis G, Kouris NI, et al · · 2022 · cited 20× · PMID 35280344 · DOI 10.21037/sci-2021-063
7. Mesenchymal Stem Cell-Derived Exosomes as a Neuroregeneration Treatment for Alzheimer's Disease.
   Shah S, Mansour HM, Aguilar TM, Lucke-Wold B. · · 2024 · cited 17× · PMID 39335626 · DOI 10.3390/biomedicines12092113
8. An update on stem cell and stem cell-derived extracellular vesicle-based therapy in the management of Alzheimer's disease.
   Jeyaraman M, Rajendran RL, Muthu S, Jeyaraman N, et al · · 2023 · cited 10× · PMID 37449130 · DOI 10.1016/j.heliyon.2023.e17808